CANCER RESEARCH HIGHLIGHTS 2008
Day 1
 2008 Hematologic Malignancy
Research Highlights
Friday, March 28, 2008
7:30 am – 3:55 pm
This activity has been designed to meet the educational needs of
advanced practice nurses and oncology certified nurses.
To educate nurses on the latest research advances in the treatment of hematologic malignancies and how to incorporate these advances into clinical practice.
Program Overview
Breakthrough data on treatment approaches for hematologic malignancies will be presented by nationally
recognized thought leaders. The conference will begin with a brief overview of select statistical concepts as
a basis for understanding published research reports to be presented during the 2-day meeting. The
remainder of Day 1 will focus on specific hematologic topics listed below. Each presentation will include
an overview of current research to be followed by a case-based discussion illustrating how the data presented
can be incorporated into clinical practice.
Topics will include:
- An Introduction to Cancer Clinical Research
- Chronic Myelogenous Leukemia (CML)
- Myelodysplastic Syndrome (MDS)
- Non-Hodgkin’s Lymphoma (NHL)
- Tumor Lysis Syndrome (TLS)
- Multiple Myeloma (MM)
A question-and-answer session will conclude each segment of the program.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanism of imatinib-resistance in CML, and identify available
therapeutic options for these patients
- Discuss the role of hypomethylating agents and immunomodulatory therapy in the treatment of MDS and the impact of
new treatment strategies on patient quality of life
- Differentiate between the diagnostic profiles of B-cell aggressive and
indolent NHLs
- Describe the toxicity profiles of monoclonal antibodies used to treat B-cell and aggressive NHLs and apply appropriate nursing
management strategies
- Describe appropriate clinical management of patients diagnosed
with TLS
- Review novel MM therapies and formulate a nursing plan for treatment-related side effects
Faculty
Beth Faiman RN, MSN, CNP, AOCN® (Chairperson)
Cleveland Clinic Taussig Cancer Center
Ms. Faiman is a nurse practitioner at the Cleveland Clinic Foundation in Cleveland, Ohio.
She is also an adjunct faculty member of Kent State University, Kent, Ohio, and Case
Western University, Cleveland, Ohio. Ms. Faiman received her master’s degree in nursing
and nurse practitioner certification from Kent State University in 2002. She is an active
author, presenter, and educator.
Beth Faiman, RN, MSN, CNP, AOCN®, reported a financial interest/relationship or affiliation in the form
of: Consultant, Celgene Corporation, Millennium Pharmaceuticals, Inc., and Novartis Pharmaceuticals
Corporation.
Carlton G. Brown, PhD, APRN, AOCN®
Georgetown University School of Nursing & Health Services
Dr. Brown is an assistant professor at the School of Nursing & Health Studies at
Georgetown University in Washington, DC. He received his doctorate in nursing from the
University of Utah in Salt Lake City. Dr. Brown’s research interests include stem cell transplant
and symptom management of patients with cancer undergoing chemotherapy. He
has written numerous articles on the subject in journals such as Nursing Research,
Seminars in Oncology Nursing, and American Journal of Nursing. He is also the president
of the Oncology Nursing Certification Corporation and an active member of the
Multinational Association of Supportive Cancer Care.
Carlton G. Brown, PhD, APRN, AOCN®, reported a financial interest/relationship or affiliation in the form
of: Consultant, Endo Pharmaceuticals; Speakers’ Bureau, Cytogen Corporation.
Hagop M. Kantarjian, MD
University of Texas M.D. Anderson Cancer Center
Dr. Kantarjian is professor of medicine, and chair of the Department of Leukemia, at the
University of Texas, M.D. Anderson Cancer Center in Houston. He received his doctor of
medicine from American University of Beirut, in Lebanon and medical oncology subspecialty
degree from the University of Texas, M.D. Anderson Cancer Center. He specializes
in chronic myeloid leukemia (CML) and acute lymphoid leukemia (ALL) with an interest in
developing new therapeutic options for these diseases. He has written and cowritten
more than 500 medical publications and abstracts, including articles on treatment options
for patients with CML and ALL.
Hagop M. Kantarjian, M.D., reported a financial interest/relationship or affiliation in the form of:
Contracted Research, Bristol-Myers Squibb Company, MGI PHARMA, INC., and Novartis
Pharmaceuticals Corporation.
Sandra E. Kurtin, RN, MS, NP, AOCN®
Arizona Cancer Center
Ms. Kurtin is a hematology/oncology nurse practitioner at the Arizona Cancer Center in
Tucson, and an adjunct clinical assistant professor at the University of Arizona College of
Nursing. She has more than 15 years of experience in oncology clinical practice and
research, and has published and lectured extensively on a variety of topics related to
oncology nursing, chemotherapy administration, and cancer research. Ms. Kurtin is a
member of the Oncology Nursing Society and the American College of Nurse
Practitioners.
Sandra E. Kurtin, RN, MS, NP, AOCN®, reported a financial interest/relationship or affiliation in the form
of: Speakers’ Bureau, Amgen, Inc., Bristol-Myers Squibb Company and ImClone Systems Inc.,
Celgene Corporation, MGI PHARMA, INC., Novartis Pharmaceuticals Corporation, Pharmion
Corporation, and sanofi-aventis, U.S.
Azra Raza MD
St. Vincent’s Comprehensive Cancer Center
Dr. Raza is professor of medicine and director of the Myelodysplastic Syndrome (MDS)
Center at St. Vincent’s Comprehensive Cancer Center in New York City where she oversees
cutting edge clinical trials. She received her doctor of medicine from Dow Medical
College in Karachi, Pakistan and completed training in internal medicine at the University
of Maryland, Franklin Square Hospital, and Georgetown/VA Medical Center in
Washington, DC. She has written more than 200 articles on myelodysplastic syndrome in
journals such as The New England Journal of Medicine, Nature, and British Journal of
Hematology. As an expert in the field, she serves on numerous national and international
panels as a reviewer, consultant, and advisor.
Azra Raza, MD, reported a financial interest/relationship or affiliation in the form of: Consultant,
Celegene Corporation, Pharmion Corporation, and Novartis Pharmaceuticals Corporation; Speakers’ Bureau, Celgene Corporation, Pharmion Corporation and Novartis Pharmaceuticals Corporation;
Contracted Research, Celgene Corporation, Pharmion Corporation, and Merck & Co., Inc.
Mollie E. Moran, MSN, CNP
The James Cancer Hospital at The Ohio State University
Ms. Moran is an oncology nurse practitioner in the Arthur G. James Cancer Hospital at
The Ohio State University, where she works in collaboration with attending physicians to
provide comprehensive care to patients with hematologic malignancies in the ambulatory
setting. She received her master’s degree from the University of Pennsylvania in
Philadelphia. Ms. Moran has more than 10 years of experience in the hematology/oncology setting, and has published and lectured extensively on hematology topics,
including management of treatment-related side effects.
Mollie E. Moran, MSN, CNP, reported a financial interest/relationship or affiliation in the form of:
Speakers’ Bureau, Genentech BioOncology, MGI PHARMA, INC., and Novartis Pharmaceuticals
Corporation.
Owen A. O’Conner, MD, PhD
Columbia University Medical Center
Dr. O'Connor is director of the Lymphoid Development and Malignancy Program at the
Herbert Irving Comprehensive Cancer Center at Columbia University in New York City. He
also serves as chief of the Lymphoma Service and associate professor of medicine in the
Division of Medical Oncology at Columbia University. Dr. O'Connor received his doctorate
from New York University and his doctor of medicine from the University of Medicine& Dentistry of New Jersey in New Brunswick. The cornerstone of his research is the translation
of basic science discoveries into therapies for hematologic malignancies including
lymphoma. To that end, his research is focused on testing promising therapeutic agents in
phase I and II clinical trials. The FDA recently approved three such agents studied in his
laboratory, one of which, pralatrexate, was designed by Dr. O'Connor in collaboration with
chemists at Memorial Sloan-Kettering Cancer Center for the treatment of patients with
T-cell lymphoma.
Owen A. O’Connor, reported a financial interest/relationship or affiliation in the form of: Speakers’ Bureau, Allos Therapeutics, Inc., Ascenta Therapeutics, Inc., Cougar Biotechnology, Inc., and
Millennium Pharmaceuticals, Inc.
Christopher R. Friese, PhD, RN, AOCN®
Harvard School of Public Health
Dr. Friese is a research fellow at the Center for Outcomes and Policy Research and an
associate clinical scientist at the Phyllis F. Cantor Center for Research in Nursing& Patient Care Services, both at the Dana-Farber Cancer Institute in Boston,
Massachusetts. He received his doctorate in nursing from the University of Pennsylvania
in Philadelphia, and is the recipient of two merit awards from the American Society of
Clinical Oncology, and a Young Investigator Award from the Multinational Association of
Supportive Care in Cancer. His research focuses on patient outcomes following cancer
treatment, and the role played by nursing staff. Dr. Friese’s research has been published
in Health Services Research, Nursing Research, Oncology Nursing Forum, and Clinical
Journal of Oncology Nursing. He lectures nationally and internationally on nursing
interventions for patients with cancer, supportive care in cancer, the delivery of safe,
high-quality cancer care, and nursing workforce issues.
Christopher R. Friese, PhD, RN, AOCN®, reported a financial interest/relationship or affiliation in the
form of: Consultant, Amgen, Inc. and MGI PHARMA, INC.; Speakers’ Bureau, Amgen, Inc.;
Ownership, Amgen, Inc. and Novartis Pharmaceuticals Corporation.
Rafael Fonseca, MD
Mayo Clinic, Scottsdale
Dr. Fonseca is professor of medicine at the Mayo Clinic College of Medicine and deputy
director of the Mayo Clinic Cancer Center in Scottsdale, Arizona. He received his doctor
of medicine from Universidad Anahuac School of Medicine in Mexico City, Mexico,
followed by a residency in internal medicine at the University of Miami/Jackson Memorial
Hospital in Florida. Dr. Fonseca’s research interests include the understanding of genetic
abnormalities associated with plasma cell disorders. He has written hundreds of journal
articles on the subject and is the recipient of numerous awards for research excellence.
Rafael Fonesca, MD, reported a financial interest/relationship or affiliation in the form of: Consultant,
Celgene Corporation and Millennium Pharmaceuticals, Inc.; Research Support, Pfizer, Inc.
Disclosure of Conflicts of Interest
The Institute for Medical Education & Research (IMER) requires instructors, planners,
managers, and other individuals who are in a position to control the content
of this activity to disclose any real or apparent conflict of interest they may have as
related to the content of this activity. All identified conflicts of interest are thoroughly
vetted by IMER for fair balance, scientific objectivity of studies mentioned in the
materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Please refer to the individual Faculty Bio’s for statements.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Madelyn T. Herzfeld, RN, BSN, OCN®, reported no areas of conflict.
Dorothy Dulko, PhD, RN, AOCNP-C, reported no areas of conflict.
Davecia Ragoonath, MS, reported no areas of conflict.
Safeguards Against Commercial Bias
IMER affirms that the content and format of its CE activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, IMER employs several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CE activities sponsored by IMER to ensure adherence to the American Nurses Credentialing Center’s criteria and operational requirements and the Accreditation Council for Continuing Medical Education’s content validation statements and resolution of any actual or perceived conflict of interest that exist.We employ three metrics as we review your materials:
1. Fair balance
a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners
Privacy Policy
When you participate in an educational activity provided by the Institute for Medical Education & Research (“IMER” or “we”), we ask you for your name, degree, affiliation, street address, telephone number, fax number, and e-mail address (the “Information”). We use that Information in the following ways:
We use the Information to grade your posttest and to send you a certificate of completion of the educational activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the Information to that company for that purpose only.
For each educational activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the Information to invite you to participate in other educational activities that IMER or its affiliates may offer.
On occasion, the commercial supporter of a educational activity will ask us for a list of the people who participated in that activity, so that it may document the first level of outcomes-based evaluation in the educational activity (i.e., who attended, which medical specialties/practices were represented, how this compares to the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will provide the supporter with your name, title and affiliation, but we will request in writing that the supporter not contact you directly for any purpose.
If our company is acquired or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
Any changes to our privacy policy will be posted here.
Method of Participation
There are no fees for participating and receiving nursing contact hours for this activity.
Participants must complete the posttest by recording the best answer to each question. Once you finished your test and completed the subsequent evaluation form, click submit test to send your responsed to us. Your test will be immediately reviewed and if you receive a passing grade of 70% or better, you will then be directed to print your certificate online.
Media
Web site
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison to recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. IMER and Bristol- Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of IMER and Bristol-Myers Squibb Company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Accreditation Statements
This educational activity for 7.2 contact hours will be provided by IMER. IMER is
an approved provider of continuing education by the Georgia Nurses Association,
an accredited approver by the American Nurses Credentialing Center’s
Commission on Accreditation.
 2008 Solid Tumor Research Highlights
Saturday, March 29, 2008
7:30 am – 3:55 pm
This activity has been designed to meet the educational
needs of advanced practice and patient care oncology nurses.
To educate nurses on the most recent research developments and their clinical applications in the treatment of solid tumors.
Program Overview
Breakthrough research data on treatment approaches for solid tumors will be presented by nationally
recognized thought leaders. Each presentation will be followed by a case-based discussion
illustrating how the scientific data presented can be incorporated into clinical practice.
Topics will include:
- Breast Cancer
- Lung Cancer
- Gastrointestinal Cancers
- Head & Neck Cancers
- Renal Cell Carcinoma
A question-and-answer session will conclude each segment of the program.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Explain how to integrate recent cancer treatment advances into current decision-making
practices and management strategies
- Discuss recent clinical trial results regarding the use of targeted therapies such as
anti-VEGF, anti-EGFR, mTOR, and multikinase inhibitor agents
- Describe how pivotal clinical trial data are shaping novel approaches to combination therapy
- Describe how pivotal clinical trial data are shaping approaches to combination therapy
- Identify nursing management strategies to minimize the side effects
caused by combination cancer therapies, including chemotherapy, targeted
therapy, and radiation
Faculty
Carrie Tompkins Stricker, PhD, RN (Chairperson)
Abramson Cancer Center of the University of Pennsylvania
Dr. Stricker is an oncology nurse practitioner within the Hematology/Oncology Division of
the Abramson Cancer Center at the University of Pennsylvania, in Philadelphia. She
received her doctorate in nursing from the University of Pennsylvania School of Nursing.
Dr. Stricker has teaching and clinical responsibilities in the Rena Rowan Breast Center,
and the University of Pennsylvania School of Nursing. She is also project manager for the
LIVESTRONG™ Survivorship Center of Excellence at the Abramson Cancer Center. In
this capacity, she helps to guide the Cancer Center’s survivorship-focused clinical and
research initiatives, particularly for breast cancer survivors. Dr. Stricker has numerous
peer-reviewed articles in journals such as Cancer Practice, Seminars in Oncology
Nursing, and the Journal of Pain and Symptom Management. She also lectures regularly
on oncology-related topics including supportive care, and cancer survivorship issues.
Carrie Tompkins Stricker, PhD, RN, reported no areas of conflict.
Charles L. Vogel, MD
Lynn Regional Cancer Center
Dr. Vogel is an internationally recognized medical oncologist in the area of breast cancer
treatment and research. He serves as the national advisor for breast cancer research at
Aptium Oncology in Los Angeles, California, as well as medical director and scientific
advisor for Cancer Research Network, Inc., while maintaining his oncology practice with
Comprehensive Cancer Care Specialists at Boca Raton Lynn Regional Cancer Center-
West, in Florida. He received his doctor of medicine from Yale University School of
Medicine in New Haven, Connecticut and his residency training at Emory University
School of Medicine in Atlanta, Georgia. In addition, he was instrumental in the opening of
the first oncology inpatient unit at Grady Memorial Hospital in Atlanta, Georgia. His principal
research focus is breast medical oncology and he has written more than 300 peerreviewed
articles and abstracts on the subject.
Charles Vogel, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, Amgen,
Inc., AstraZeneca Pharmaceuticals LP, sanofi-aventis, U.S., Breast Cancer Internal Research Group,
Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline plc., Pfizer, Inc., Roche
Laboratories, Inc., and sanofi-aventis U.S.; Speakers' Bureau, Amgen, Inc., AstraZeneca Pharmaceuticals
LP, Genentech BioOncology, GlaxoSmithKline plc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.,
Roche Laboratories, Inc., and sanofi-aventis U.S.; Contracted Research, Amgen, Inc., AstraZeneca
Pharmaceuticals LP, Breast Cancer Internal Research Group, BioNovo, Inc., Genentech BioOncology,
GlaxoSmithKline plc., National Surgical Adjuvant Breast and Bowel Project, Pfizer, Inc., Roche
Laboratories, Inc., sanofi-aventis U.S., Sopherion Therapeutics, Inc., and Taiho Pharmaceutical Co., Ltd.
Beth A. Eaby MSN, CRNP, OCN®
Abramson Cancer Center of the University of Pennsylvania
Ms. Eaby is a board certified nurse practitioner and a nationally certified oncology nurse.
She received her master's degree in nursing from Temple University in Philadelphia,
Pennsylvania. She specializes in the treatment of patients with lung cancer and has
written numerous articles on the subject which have been published in The Oncologist,
Journal of Symptom Management, and Cancer Investigation. Ms. Eaby is a member of
the Oncology Nursing Society and serves as president of her local chapter.
Beth A. Eaby, MSN, CRNP, OCN®, reported no areas of conflict.
Mark A. Socinski, MD
Lineberger Comprehensivce Cancer Center
University of North Carolina
Dr. Socinski is an associate professor of medicine and member of the Multidisciplinary
Thoracic Oncology Program at the Lineberger Comprehensive Cancer Center at the
University of North Carolina at Chapel Hill. He received his doctor of medicine from the
University of Vermont College of Medicine in Burlington and completed training in internal
medicine at Beth Israel Deaconess Medical Center at Harvard Medical School in Boston,
Massachusetts. Dr. Socinski and colleagues were instrumental in the establishment of the
Multidisciplinary Thoracic Oncology Program at the University of North Carolina in 1995. He
is an active member of the Respiratory Core Committee of the Cancer and Acute Leukemia
Group B (CALGB), the American College of Chest Physicians, and the American Society of
Clinical Oncology. In addition, he has written and cowritten many articles, abstracts, book
chapters, and monographs predominantly focused on issues in thoracic oncology.
Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of: Speakers'
Bureau, Eli Lilly and Company, Genentech BioOncology, and sanofi-aventis, U.S.; Contracted
Research, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, Pfizer,
Inc., and sanofi-aventis, U.S.
Bridget O’Brien, ND, APRN, BC-FNP, AOCNP®
Northwestern Medical Faculty Foundation
Ms. O’Brien is a nurse practitioner in the Division of Gastroenterology at Northwestern
Medical Faculty Foundation in Chicago, Illinois. She received her doctor of nursing from
Rush University, College of Nursing, also in Chicago, Illinois. She is an active member of
several professional organizations and has served as chair of the Eastern Cooperative
Oncology Group Nursing Committee since 1996. Ms. O’Brien lectures extensively and
has written numerous articles on topics related to gastrointestinal malignancies, including
therapeutic options and symptom management.
Bridget O'Brien, ND, APRN, BC-FNP, AOCNP®, reported a financial interest/relationship or affiliation in
the form of: Consultant, Bristol-Myers Squibb Company and ImClone Systems Inc.; Speakers' Bureau,
Novartis Pharmaceuticals Corporation.
M. Wasif Saif, MD, MBBS
Yale University School of Medicine
Dr. Saif is associate professor at Yale University School of Medicine and co-director of the
Gastrointestinal Cancers Program at Yale Cancer Center in New Haven, Connecticut. He
received his doctor of medicine from King Edward Medical College in Lahore, Pakistan.
He is an expert in gastrointestinal cancers, with a special interest in pancreatic and
colorectal cancers. Dr. Saif has written and cowritten hundreds of articles, book chapters,
and abstracts on gastrointestinal cancers, including topics such as therapeutic options
and side effect management.
M. Wasif Saif, MD, MBBS, reported a financial interest/relationship or affiliation in the form of:
Consultant, Amgen, Inc., Bristol-Myers Squibb Company and ImClone Systems Inc., Genentech
BioOncology, Roche Laboratories, Inc., and sanofi-aventis U.S.; Speakers’ Bureau, Amgen, Inc., Bristol-
Myers Squibb Company and ImClone Systems Inc., Genentech BioOncology, Roche Laboratories, Inc.,
and sanofi-aventis U.S.; Contracted Research, Biogen Idec, Taiho Pharmaceutical Co., Ltd., Bristol-
Myers Squibb Company and ImClone Systems Inc., and Avalon Pharmaceuticals, Inc.
Marshall Posner, MD
Dana-Farber Cancer Institute
Dr. Posner is an associate professor of medicine at Harvard Medical School in
Cambridge, Massachusetts, medical director of the Head and Neck Oncology Program at
the Dana-Farber Cancer Institute, and director of the Human Monoclonal Antibody
Laboratory of Beth Israel Deaconess Medical Center, both in Boston. He received his
doctor of medicine from Tufts University School of Medicine, in Boston. Dr. Posner has
served as principal investigator on numerous head and neck cancer clinical and translational
research trials and has published more than 160 peer-reviewed basic science and
clinical studies. He is also a member of the editorial board of several journals including
the Journal of Clinical Oncology, American Journal of Clinical Oncology, and Oral
Oncology.
Marshall Posner, MD, reported a financial interest/relationship or affiliation in the form of: Contracted
Research, sanofi-aventis, U.S.
Laura S. Wood, RN, MSN, OCN®
Cleveland Clinic Taussig Cance Center
Ms. Wood is coordinator of renal cancer clinical research in the Experimental
Therapeutics Program at the Taussig Cancer Center of the Cleveland Clinic Foundation in
Cleveland, Ohio. She received her master's degree in nursing from Kent State University
in Kent, Ohio. A national and international lecturer on topics related to oncology nursing,
she has written journal articles on therapeutic approaches and nursing management
strategies for the care of patients with cancer. Ms. Wood was the recipient of the 2004
Oncology Nursing Society Excellence in Biotherapy Nursing Award and the 2005 Emma
Barr Award for Clinical Excellence from the Cleveland Clinic Foundation.
Laura S. Wood, RN, MSN, OCN®, reported a financial interest/relationship or affiliation in the form of:
Speakers' Bureau, Bayer Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., Pfizer, Inc., and
Wyeth Pharmaceuticals.
Robert Motzer, MD
Memorial Sloan-Kettering Cancer Center
Dr. Motzer is a nationally recognized genitourinary medical oncologist at Memorial Sloan-
Kettering Cancer Center. He received his doctor of medicine from the University of
Michigan Medical School in Ann Arbor. Has has led more than 50 clinical trials in patients
with kidney cancer. Dr. Motzer’s research aided in the identification of the targeted
antiangiogenesis agents sunitinib and temsirolimus. He was also instrumental in the
development of a system to predict treatment outcomes for patients undergoing therapy
for advanced kidney cancer.
Robert Motzer, MD, reported a financial interest/relationship or affiliation in the form of: Speakers' Bureau,
Bayer Pharmaceuticals Corporation, and Onyx Pharmaceuticals, Inc.; Contracted Research, Pfizer, Inc.,
Genentech BioOncology, Novartis Pharmaceuticals Corporation, and Wyeth Pharmaceuticals.
Disclosure of Conflicts of Interest
The Institute for Medical Education & Research (IMER) requires instructors, planners,
managers, and other individuals who are in a position to control the content
of this activity to disclose any real or apparent conflict of interest they may have as
related to the content of this activity. All identified conflicts of interest are thoroughly
vetted by IMER for fair balance, scientific objectivity of studies mentioned in the
materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Please refer to the individual Faculty Bio’s for statements.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Madelyn T. Herzfeld, RN, BSN, OCN®, reported no areas of conflict.
Dorothy Dulko, PhD, RN, AOCNP-C, reported no areas of conflict.
Davecia Ragoonath, MS, reported no areas of conflict.
Safeguards Against Commercial Bias
IMER affirms that the content and format of its CE activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, IMER employs several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CE activities sponsored by IMER to ensure adherence to the American Nurses Credentialing Center’s criteria and operational requirements and the Accreditation Council for Continuing Medical Education’s content validation statements and resolution of any actual or perceived conflict of interest that exist.We employ three metrics as we review your materials:
1. Fair balance
a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners
Privacy Policy
When you participate in an educational activity provided by the Institute for Medical Education & Research (“IMER” or “we”), we ask you for your name, degree, affiliation, street address, telephone number, fax number, and e-mail address (the “Information”). We use that Information in the following ways:
We use the Information to grade your posttest and to send you a certificate of completion of the educational activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the Information to that company for that purpose only.
For each educational activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the Information to invite you to participate in other educational activities that IMER or its affiliates may offer.
On occasion, the commercial supporter of a educational activity will ask us for a list of the people who participated in that activity, so that it may document the first level of outcomes-based evaluation in the educational activity (i.e., who attended, which medical specialties/practices were represented, how this compares to the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will provide the supporter with your name, title and affiliation, but we will request in writing that the supporter not contact you directly for any purpose.
If our company is acquired or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
Any changes to our privacy policy will be posted here.
Method of Participation
There are no fees for participating and receiving nursing contact hours for this activity.
Participants must complete the posttest by recording the best answer to each question. Once you finished your test and completed the subsequent evaluation form, click submit test to send your responsed to us. Your test will be immediately reviewed and if you receive a passing grade of 70% or better, you will then be directed to print your certificate online.
Media
Web site
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison to recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. IMER and Bristol- Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of IMER and Bristol-Myers Squibb Company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Accreditation Statements
This educational activity for 7.1 contact hours will be provided by IMER. IMER is
an approved provider of continuing education by the Georgia Nurses Association,
an accredited approver by the American Nurses Credentialing Center’s
Commission on Accreditation.
Sponsored by:
. |
